Avectas is a cell engineering technology business, enabling the manufacture of cell therapies. Avectas’ technology, Solupore®, delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T cells for immuno-oncology and gene editing applications. Solupore® utilizes a membrane disruptive approach to rapidly deliver advanced molecules to cells. It is a simple, rapid and gentle process that yields superior engineered cells. Solupore® results in improved cell processing times and cell health relative to viral vectors and electroporation, leading to a more cost-effective manufacturing process. Avectas is currently partnering with immuno-oncology and gene editing businesses to deliver their proprietary molecules. Avectas is also seeking therapeutic molecules to in-license as the core of a therapeutic program.
Our vision is to become the gold standard in vector-free intracellular delivery.
Intracellular delivery is achieved by reversible permeabilization using a fluid handling process.
Project: 811360 — SOLUPORE
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 738774.